NEWARK, Calif.--(BUSINESS WIRE)-- Vector Laboratories, the pioneer of innovative proteomic and glycomic solutions, today announced the launch of its novel product Glysite™ Scout Glycan Screening Kits. These immunofluorescence (IF) kits are fully integrated for the detection of glycan expression in tissue sections and will support the ability to profile and characterize complex glycans in biological systems.

From tumor progression to viral capture to drug discovery, scientists are exploring the role of glycan modifications in normal and disease states. Vector Laboratories’ Glysite Scout Glycan Screening Kits will enable researchers to begin to understand the relevance of glycomics in their samples for association with post-translational protein modifications and biomarkers of disease. Vector Laboratories’ curated lectin selection allows researchers to detect the presence or absence of all major surface glycan motifs in a sample, offering insight into disease progression, determining the effect of a treatment or stimulus, or allowing for better characterization of cell and tissue types.

“Glycan research is continuing to grow in popularity, with more and more scientists expressing interest in exploring glycobiology because of the potential impact it has on critical fields of disease study such as oncology,” says CEO of Vector Laboratories Lisa V Sellers, PhD. “But we’re finding that researchers need help getting started, so it’s our mission to not only provide a reliable product, but to also offer our customers unmatched technical expertise and guidance to allow them to continue to move science forward.”

Glycans are known to participate in numerous fundamental biological processes and dysregulation has been impacted in many disease states. For example, the glycome can influence cancer progression in numerous ways, which generates various biomarkers that can be used for cancer detection. Research exploring how cancer alters glycosylation mechanisms has the added benefit of highlighting potential markers that can be targeted to correct cancer-induced modifications.

“Glycobiology is a complex field with a lot of untapped potential,” says Pamela James, PhD, Vice President, Product at Vector Laboratories. “As a scientific community, we have not breached the surface of what is possible in this area of study, but that’s what makes this exciting. Throughout more than 45 years of experience, we’ve leveraged our manufacturing excellence to produce products that will help propel our customers and the industry forward.”

Vector Laboratories was the first company to commercialize avidin-biotin enzyme complex kits for immunohistochemistry and antifade mounting media for immunofluorescence. It has since introduced over 600 reliable reagents and kits through four decades of leadership in labeling and detection technologies. Explore more vectorlabs.com/glysite-scout.

About Vector Laboratories

Vector Laboratories empowers scientific advances with innovative proteomic and glycomic solutions. Supporting industries worldwide for 45 years and counting, Vector Laboratories is a trusted manufacturing partner with unmatched technical expertise and a culture of service. Customers rely on Vector Laboratories’ immunofluorescence, immunohistochemistry, glycobiology and bioconjugation products and custom manufacturing capabilities to move science forward, with impact. Vector Laboratories’ market-tested product portfolio provides the critical tools researchers need to precisely visualize and study tissues and cells, and to ultimately tackle today’s biggest healthcare challenges. The company’s products and technologies have been cited in more than 350,000 peer-reviewed publications and its catalog and custom products are relied upon by laboratories around the world. Headquartered in Newark, CA, Vector Laboratories includes a global network of more than 40 distributors. For more information about Vector Laboratories, please visit: www.vectorlabs.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220719005262/en/